+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Addison's Disease Therapeutics Market 2019-2023 - Product Image

Global Addison's Disease Therapeutics Market 2019-2023

  • ID: 4770398
  • Report
  • April 2019
  • Region: Global
  • 118 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Merck & Co. Inc.
  • Novartis AG
  • Pfizer Inc.
  • MORE
About this market

The favorable reimbursement scenario is one of the key factors expected to trigger the market growth during the forecast period. Reimbursement is quite essential for ensuring wider patient access to the Internet. Insurers are increasingly providing complete reimbursement for most of the drugs indicated for the treatment of adrenal insufficiency. In addition, governments and healthcare agencies are further investing a huge amount of money in improving national or regional health. As a result, the supporting reimbursement policies are expected to contribute significantly to the Addison’s disease therapeutics market growth during the forecast period. The analysts have predicted that the Addison’s disease therapeutics market will register a CAGR of nearly 4% by 2023.

Market Overview

Special drug designations

Special drug designations promote vendors to come up with better drugs in the market, which extends the product offerings to patients and their adherence to therapeutic alternatives. This, in turn, drives the market growth.

Adverse effects associated with available drugs

The drugs that are available in the market include glucocorticoids and mineralocorticoids, which are associated with harmful side effects. These side effects exert a negative impact on the quality of life of the patients and reduce their willingness to continue treatment with the drugs.

For the detailed list of factors that will drive and challenge the growth of the Addison’s disease therapeutics market during 2019-2023, view the full report.

Competitive Landscape

The market appears to be moderately fragmented with the presence of several market players. Various companies are focusing on investing in R&D of the medicines for curing rare and orphan diseases, including Addison’s disease, along with the chronic illnesses such as central nervous system (CNS) disorders, and cancer. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Merck & Co. Inc.
  • Novartis AG
  • Pfizer Inc.
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT
  • Preface
  • Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 04: MARKET SIZING
  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 06: MARKET SEGMENTATION BY PRODUCT
  • Market segmentation by product
  • Comparison by product
  • Oral drugs - Market size and forecast 2018-2023
  • Parenteral drugs - Market size and forecast 2018-2023
  • Market opportunity by product
PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE
  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity
PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 11: MARKET TRENDS

PART 12: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
  • Competitive scenario
PART 13: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Bristol-Myers Squibb Company
  • Merck & Co. Inc.
  • Novartis AG
  • Pfizer Inc.
  • Takeda Pharmaceutical Company Limited
PART 14: APPENDIX
  • Research methodology
  • List of abbreviations
  • Definition of vendors classification
List of Exhibits
Exhibit 01: Global rare diseases therapeutics market
Exhibit 02: Segments of global rare diseases therapeutics market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 09: Five forces analysis 2018
Exhibit 10: Five forces analysis 2023
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition - Five forces 2018
Exhibit 17: Product - Market share 2018-2023 (%)
Exhibit 18: Comparison by product
Exhibit 19: Oral drugs - Market size and forecast 2018-2023 ($ millions)
Exhibit 20: Oral drugs - Year-over-year growth 2019-2023 (%)
Exhibit 21: Parenteral drugs - Market size and forecast 2018-2023 ($ millions)
Exhibit 22: Parenteral drugs - Year-over-year growth 2019-2023 (%)
Exhibit 23: Market opportunity by product
Exhibit 24: Customer landscape
Exhibit 25: Market share by geography 2018-2023 (%)
Exhibit 26: Geographic comparison
Exhibit 27: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 28: North America - Year-over-year growth 2019-2023 (%)
Exhibit 29: Top 3 countries in North America
Exhibit 30: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 31: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 32: Top 3 countries in Europe
Exhibit 33: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 34: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 35: Top 3 countries in Asia
Exhibit 36: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 37: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 38: Top 3 countries in ROW
Exhibit 39: Key leading countries
Exhibit 40: Market opportunity
Exhibit 41: Reformulated corticosteroids
Exhibit 42: Impact of drivers and challenges
Exhibit 43: Vendor landscape
Exhibit 44: Landscape disruption
Exhibit 45: Vendors covered
Exhibit 46: Vendor classification
Exhibit 47: Market positioning of vendors
Exhibit 48: Bristol-Myers Squibb Company - Vendor overview
Exhibit 49: Bristol-Myers Squibb Company - Business segments
Exhibit 50: Bristol-Myers Squibb Company - Organizational developments
Exhibit 51: Bristol-Myers Squibb Company - Geographic focus
Exhibit 52: Bristol-Myers Squibb Company - Key offerings
Exhibit 53: Merck & Co. Inc. - Vendor overview
Exhibit 54: Merck & Co. Inc. - Business segments
Exhibit 55: Merck & Co. Inc. - Organizational developments
Exhibit 56: Merck & Co. Inc. - Geographic focus
Exhibit 57: Merck & Co. Inc. - Segment focus
Exhibit 58: Merck & Co. Inc. - Key offerings
Exhibit 59: Novartis AG - Vendor overview
Exhibit 60: Novartis AG - Business segments
Exhibit 61: Novartis AG - Organizational developments
Exhibit 62: Novartis AG - Geographic focus
Exhibit 63: Novartis AG - Segment focus
Exhibit 64: Novartis AG - Key offerings
Exhibit 65: Pfizer Inc. - Vendor overview
Exhibit 66: Pfizer Inc. - Business segments
Exhibit 67: Pfizer Inc. - Organizational developments
Exhibit 68: Pfizer Inc. - Geographic focus
Exhibit 69: Pfizer Inc. - Segment focus
Exhibit 70: Pfizer Inc. - Key offerings
Exhibit 71: Takeda Pharmaceutical Company Limited - Vendor overview
Exhibit 72: Takeda Pharmaceutical Company Limited - Business segments
Exhibit 73: Takeda Pharmaceutical Company Limited - Organizational developments
Exhibit 74: Takeda Pharmaceutical Company Limited - Geographic focus
Exhibit 75: Takeda Pharmaceutical Company Limited - Key offerings
Exhibit 76: Validation techniques employed for market sizing
Exhibit 77: Definition of vendors classification
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4

FEATURED COMPANIES

  • Merck & Co. Inc.
  • Novartis AG
  • Pfizer Inc.
  • MORE
Global Addison’s Disease Therapeutics Market 2019-2023

The author of the report recognizes the following companies as the key players in the global Addison’s disease therapeutics market: Bristol-Myers Squibb Company, Merck & Co. Inc., Novartis AG, Pfizer Inc., and Takeda Pharmaceutical Company Limited.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the availability of clinical guidelines.”

According to the report, one of the major drivers for this market is the special drug designations.

Further, the report states that one of the major factors hindering the growth of this market is the adverse effects associated with available drugs.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 4
  • Bristol-Myers Squibb Company
  • Merck & Co. Inc.
  • Novartis AG
  • Pfizer Inc.
  • Takeda Pharmaceutical Company Limited
Note: Product cover images may vary from those shown
Adroll
adroll